Evidence map›Paper›PMID 32061334›Full record

ArticleThe Lancet. Respiratory medicine2020

Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study.

Stijn E Verleden, Naoya Tanabe, John E McDonough, Dragoş M Vasilescu, Feng Xu, Wim A Wuyts, Davide Piloni, Laurens De Sadeleer, Stijn Willems, Cindy Mai and 13 more

Open access · greenAbstract read
In one paragraph

Article in The Lancet. Respiratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 119 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Progenitor Resilience and the Early Onset of Chronic Lung Diseases: NHLBI workshop report.American journal of respiratory cell and molecular biology · 2026
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 5 countries.

Stijn E VerledenDepartment of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
Naoya TanabeUniversity of British Columbia, Department of Pathology and Center for Heart and Lung Innovation at St Paul's Hospital, Vancouver, BC, Canada; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
John E McDonoughDepartment of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
Dragoş M VasilescuUniversity of British Columbia, Department of Pathology and Center for Heart and Lung Innovation at St Paul's Hospital, Vancouver, BC, Canada.
Feng XuUniversity of British Columbia, Department of Pathology and Center for Heart and Lung Innovation at St Paul's Hospital, Vancouver, BC, Canada.
Wim A WuytsDepartment of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
Davide PiloniDepartment of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium; The Respiratory Disease Unit, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Laurens De SadeleerDepartment of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
Stijn WillemsDepartment of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
Cindy MaiDepartment of Radiology, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
Jeroen HostensThe Bruker microCT, Kontich, Belgium.
Joel D CooperDepartment of Thoracic Surgery University of Pennsylvania, Philadelphia, PA, USA.
Erik K VerbekenDepartment of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
Johny VerschakelenDepartment of Radiology, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
Craig J GalbanDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.
Dirk E Van RaemdonckDepartment of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
Thomas V ColbyDepartment of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ, USA.
Marc DecramerDepartment of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
Geert M VerledenDepartment of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
Naftali KaminskiSection of Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CT, USA.
Tillie-Louise HackettUniversity of British Columbia, Department of Pathology and Center for Heart and Lung Innovation at St Paul's Hospital, Vancouver, BC, Canada.
Bart M VanaudenaerdeDepartment of Clinical and Experimental Medicine, Division of Respiratory Diseases, Katholieke Universiteit Leuven, University Hospitals Leuven, Leuven, Belgium.
James C HoggUniversity of British Columbia, Department of Pathology and Center for Heart and Lung Innovation at St Paul's Hospital, Vancouver, BC, Canada. Electronic address: jim.hogg@hli.ubc.ca.
KU Leuven · BEUniversity of British Columbia · CAIstituti di Ricovero e Cura a Carattere Scientifico · ITMayo Clinic Hospital · USUniversity of Michigan · USUniversity of Pennsylvania · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
TrainingU54HG008540 · NHGRI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAHAR, IVET, COOPER, GREGORY F. · 2014 to 2018
$12.8M
Genomic Analysis of Tissue and Cellular Heterogeneity in IPFR01HL127349 · NHLBI · YALE UNIVERSITY · PI BENOS, PANAGIOTIS V, KAMINSKI, NAFTALI · 2015 to 2025
$5.9M
Alveolar DevMAPU01HL122626 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMBALAVANAN, NAMASIVAYAM, HAGOOD, JAMES S. · 2014 to 2018
$3.7M
Epithelial Protective Effects of Thyroid Hormone Signaling in FibrosisR01HL141852 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2019 to 2022
$3.4M
Normal Aging Lung Cell Atlas (NALCA)U01HL145567 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2019 to 2022
$2.8M
An Early Imaging Marker of EmphysemaR01HL139690 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GALBAN, CRAIG J · 2019 to 2022
$1.9M
CT-based Biomarker for Diagnosis of COPD Phenotypes and Disease ProgressionR44HL118837 · NHLBI · IMBIO, LLC · PI GALBAN, CRAIG J, HATT, CHARLES R · 2013 to 2016
$1.8M
NCATS NIH HHS UL1 TR001863NHGRI NIH HHS U54 HG008540NHLBI NIH HHS R01 HL127349NHLBI NIH HHS R01 HL139690NHLBI NIH HHS R01 HL141852NHLBI NIH HHS R44 HL118837NHLBI NIH HHS U01 HL122626NHLBI NIH HHS U01 HL145567
6 · The paper itself

Abstract

backgroundThe observation that patients with idiopathic pulmonary fibrosis (IPF) can have higher than normal expiratory flow rates at low lung volumes led to the conclusion that the airways are spared in IPF. This study aimed to re-examine the hypothesis that airways are spared in IPF using a multiresolution imaging protocol that combines multidetector CT (MDCT), with micro-CT and histology.

methodsThis was a retrospective cohort study comparing explanted lungs from patients with severe IPF treated by lung transplantation with a cohort of unused donor (control) lungs. The donor control lungs had no known lung disease, comorbidities, or structural lung injury, and were deemed appropriate for transplantation on review of the clinical files. The diagnosis of IPF in the lungs from patients was established by a multidisciplinary consensus committee according to existing guidelines, and was confirmed by video-assisted thoracic surgical biopsy or by pathological examination of the contralateral lung. The control and IPF groups were matched for age, sex, height, and bodyweight. Samples of lung tissue were compared using the multiresolution imaging approach: a cascade of clinical MDCT, micro-CT, and histological imaging. We did two experiments: in experiment 1, all the lungs were randomly sampled; in experiment 2, samples were selected from regions of minimal and established fibrosis. The patients and donors were recruited from the Katholieke Universiteit Leuven (Leuven, Belgium) and the University of Pennsylvania Hospital (Philadelphia, PA, USA). The study took place at the Katholieke Universiteit Leuven, and the University of British Columbia (Vancouver, BC, Canada).

findingsBetween Oct 5, 2009, and July 22, 2016, explanted lungs from patients with severe IPF (n=11), were compared with a cohort of unused donor (control) lungs (n=10), providing 240 samples of lung tissue for comparison using the multiresolution imaging approach. The MDCT specimen scans show that the number of visible airways located between the ninth generation (control 69 [SD 22] versus patients with IPF 105 [33], p=0·0023) and 14th generation (control 9 [6] versus patients with IPF 49 [28], p<0·0001) of airway branching are increased in patients with IPF, which we show by micro-CT is due to thickening of their walls and distortion of their lumens. The micro-CT analysis showed that compared with healthy (control) lung anatomy (mean 5·6 terminal bronchioles per mL [SD 1·6]), minimal fibrosis in IPF tissue was associated with a 57% loss of the terminal bronchioles (mean 2·4 terminal bronchioles per mL [SD 1·0]; p<0·0001), the appearance of fibroblastic foci, and infiltration of the tissue by inflammatory immune cells capable of forming lymphoid follicles. Established fibrosis in IPF tissue had a similar reduction (66%) in the number of terminal bronchioles (mean 1·9 terminal bronchioles per mL [SD 1·4]; p<0·0001) and was dominated by increased airspace size, Ashcroft fibrosis score, and volume fractions of tissue and collagen.

interpretationSmall airways disease is a feature of IPF, with significant loss of terminal bronchioles occuring within regions of minimal fibrosis. On the basis of these findings, we postulate that the small airways could become a potential therapeutic target in IPF.

fundingKatholieke Universiteit Leuven, US National Institutes of Health, BC Lung Association, and Genentech.

Indexed as

BronchiolesFemaleHumansIdiopathic Pulmonary FibrosisLungLung TransplantationMaleMiddle AgedMultidetector Computed TomographyMultimodal ImagingRetrospective StudiesX-Ray Microtomography

Identifiers

PMID32061334
PMCPMC7292784
OpenAlexW3005995130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.